CEACAM5 and gastric cancer: CEA was positive in 23.0%, 25.6%, and 39.5% of patients, while CA19‐9 was positive in 19.9%, 32.2%, and 44.7% of patients with Stage II, III, and IV gastric cancers, respectively.31